Pharmacokinetics and Safety of Polaprezinc Granules Oral Administration in Healthy Chinese Volunteers Under Fasting and Fed Conditions.

The study aimed to demonstrate bioequivalence between generic and original polaprezinc granules by comparing pharmacokinetic (PK) profiles in healthy Chinese subjects under fasting and fed conditions. This PK investigation was conducted with two independent, randomized, open-label, single-dose, two-period, cross-over studies. Healthy Chinese fasting (N = 24, 75 mg) or fed (N = 24, 300 mg) subjects randomly received a single oral dose of the test or reference polaprezinc granules at each period. Blood samples were collected pre- and post-dose for up to 12 h. Blood zinc was determined using a validated ICP-MS method. Primary PK endpoints were calculated using non-compartmental methods, including peak concentration (Cmax) and the areas under the plasma concentration-time curve (AUC0-t, AUC0-∞). The geometric mean ratios (GMR) in primary PK endpoints between the test and reference products with 90% confidence intervals (CI) were calculated. Treatment-emergent adverse events were assessed. In the fasting study, Cmax, AUC0-t and AUC0-∞ were 1.30 ± 0.30 μg/mL, 4.06 ± 1.13 h·μg/mL, and 4.43 ± 1.04 h·μg/mL following 75 mg test product. In the fed study, Cmax, AUC0-t and AUC0-∞ were 0.91 ± 0.26 μg/mL, 3.26 ± 1.06 h·μg/mL, and 3.37 ± 1.07 h·μg/mL following 300 mg test product. The reference product had comparable PK profiles. All 90% CIs of GMRs in Cmax, AUC0-t and AUC0-∞ between the two products were within 80.0%-125.0%. Both study products were well-tolerated with no serious adverse events. The generic and original polaprezinc granules were bioequivalent by pharmacokinetic comparisons in healthy Chinese subjects under fasting and fed conditions. The two polaprezinc formulations were well-tolerated with no new safety signals. Trial Registration: CTR20210011.